Suzhou Medilink Therapeutics
Latest round
- Series B
Last raised
- Mar 2022
Total raised
- $120M
Investors
- 6
About Suzhou Medilink Therapeutics
Founded in 2020 and based in Suzhou, China, Medilink Therapeutics has focused its efforts on ADC development. In March 2022, Suzhou Medilink Therapeutics Ltd. Medilink develops ADC candidates based on its TMALIN® platform, designed for high drug-antibody ratio, stability, and tumor microenvironment activation. Its key drug candidates include: L201, targeting B7-H3, granted FDA Breakthrough Therapy designation (June 2025) and currently in Phase III for small cell lung cancer (SCLC) and nasopharyngeal cancer; YL211, a c-MET targeting ADC under global license to Roche for solid tumors, with Roche leading global development following IND initiation in 2024; YL217 (CDH17 ADC, IND accepted May 2025) and YL242 (VEGF ADC, FDA/CDE accepted) are advancing toward clinical stages. Medilink also engages in licensing and collaboration services with global pharma partners, leveraging its platform strengths. The company generates revenue from milestone and licensing payments under collaboration agreements (with Roche, Zai Lab, BioNTech), and anticipates future royalty income tied to ADC commercialization. Additional sources include research service fees and platform licensing.
Who invested in Suzhou Medilink Therapeutics
6 investors across 2 rounds
See all investors in Suzhou Medilink Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Suzhou Medilink Therapeutics
Who invested in Suzhou Medilink Therapeutics?
Suzhou Medilink Therapeutics has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Suzhou Medilink Therapeutics raised?
Suzhou Medilink Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Suzhou Medilink Therapeutics last raise money?
Suzhou Medilink Therapeutics's most recent round on record is a Series B, in Mar 2022.
What does Suzhou Medilink Therapeutics do?
Founded in 2020 and based in Suzhou, China, Medilink Therapeutics has focused its efforts on ADC development.
Where is Suzhou Medilink Therapeutics headquartered?
Suzhou Medilink Therapeutics is headquartered in Suzhou, China.
Which VCs invest in companies like Suzhou Medilink Therapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Suzhou Medilink Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Suzhou Medilink Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.